Chalazion Treatment: A Concise Review of Clinical Trials.
Tashbayev B, Chen X, Utheim TP.
Curr Eye Res. 2024 Feb;49(2):109-118. doi: 10.1080/02713683.2023.2279014. Epub 2024 Jan 18.
[Hordeolum and chalazion : (Differential) diagnosis and treatment].
Loth C, Miller CV, Haritoglou C, Messmer ESBM.
Ophthalmologe. 2022 Jan;119(1):97-108. doi: 10.1007/s00347-021-01436-y. Epub 2021 Aug 11.
The lowly chalazion.
Kim ES, Afshin EE, Elahi E.
Surv Ophthalmol. 2023 Jul-Aug;68(4):784-793. doi: 10.1016/j.survophthal.2022.11.002. Epub 2022 Nov 15.
Establishment of a human meibomian gland carcinoma cell model and analysis of differently expressed genes.
Zhang C, Zhu L, Liu X, Jiang M, Tang Q, Xu F, Lin T, He Y.
Exp Eye Res. 2022 Jun;219:108983. doi: 10.1016/j.exer.2022.108983. Epub 2022 Feb 25.
Evaluation of Meibomian Gland Dysfunction in Polycystic Ovary Syndrome and Obesity.
Baser G, Yildiz N, Calan M.
Curr Eye Res. 2017 May;42(5):661-665. doi: 10.1080/02713683.2016.1233985. Epub 2016 Oct 28.
Evaluation of Meibomian Gland Function after Therapy of Eyelid Tumors at Palpebral Margin with Super Pulse CO(2) Laser.
Zhao S, Duan J, Zhang J, Gong L.
Dis Markers. 2022 Jan 17;2022:8705436. doi: 10.1155/2022/8705436. eCollection 2022.
Another Etiological Factor of Meibomian Gland Loss in Patients with Polycystic Ovary Syndrome: Inflammation.
Acet Y, Sarikaya S.
J Ocul Pharmacol Ther. 2022 Nov;38(9):626-634. doi: 10.1089/jop.2022.0097. Epub 2022 Sep 30.
Evaluation of Meibomian gland dysfunction using meibography in patients with xeroderma pigmentosum.
Marcos AAA, Freitas D, Hazarbassanov RM, Fernandes AG, Castro LP, Melo DBV, Menck CFM, Morales MC, Gomes JÁP, Belfort Neto R, Singh AD.
Arq Bras Oftalmol. 2024 Mar 4;87(2):e20220319. doi: 10.5935/0004-2749.2022-0319. eCollection 2024.
Evaluation of meibomian gland morphology and anterior segment parameters by Sirius topography systems in polycystic ovary syndrome.
Balıkçı AT, Ulutaş HG, Özgen GA.
Indian J Ophthalmol. 2022 Aug;70(8):2922-2928. doi: 10.4103/ijo.IJO_6_22.
Upregulated MYC expression and p53 mutations may contribute to the oncogenesis of canine Meibomian gland carcinomas.
Peterson C, Hicks JL, De Marzo AM, Campbell AA, Eberhart CG, Dubielzig RR, Teixeira LB.
Vet Pathol. 2023 Mar;60(2):185-189. doi: 10.1177/03009858221143400. Epub 2022 Dec 21.
